DOCSLIB.ORG

Activation Regulates IL-2 Expression in T Lymphocyte Immediate-Early Transcriptional Factor, Krüppel-Like Factor 2, a Novel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Activation Regulates IL-2 Expression in T Lymphocyte Immediate-Early Transcriptional Factor, Krüppel-Like Factor 2, a Novel Krüppel-Like Factor 2, a Novel Immediate-Early Transcriptional Factor, Regulates IL-2 Expression in T Lymphocyte Activation This information is current as of September 25, 2021. Jinghai Wu and Jerry B. Lingrel J Immunol 2005; 175:3060-3066; ; doi: 10.4049/jimmunol.175.5.3060 http://www.jimmunol.org/content/175/5/3060 Downloaded from References This article cites 35 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/175/5/3060.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Kru¨ppel-Like Factor 2, a Novel Immediate-Early Transcriptional Factor, Regulates IL-2 Expression in T Lymphocyte Activation1 Jinghai Wu and Jerry B. Lingrel2 Ag presentation to T lymphocytes and subsequent activation are characterized by a cascade of signaling events, some of which result in the transcriptional activation of a diverse set of genes. An important example is the induction of the IL-2 gene, which is a critical event in the escalation of T cell activation. Previous studies have found that expression of Kru¨ppel-like factor 2 (KLF2), a zinc finger transcription factor, is extinguished after T cell activation. However, the biological role of KLF2 during T cell activation is still unknown. In this study we found that KLF2 protein degradation is delayed, and KLF2 expression is up-regulated during the early stage of T cell activation in primary T cells. Within a few hours, this process is reversed, and KLF2 expression Downloaded from is turned off. Next, we found that the expression of KLF2 significantly increases IL-2 production 4-fold in activated T cells, resulting from activation of the IL-2 promoter. By narrowing down the 2.0-kb IL-2 promoter region, we found that the KLF2 responsive element in the IL-2 promoter is a CACCC element, the KLF consensus binding motif. Moreover, KLF2 binds to this promoter in vivo under different conditions. Our studies show that KLF2 regulates IL-2 promoter activity in the earliest stages of T cell activation, indicating that KLF2 may act as a novel immediate-early transcriptional factor to maximally prime T cell activation. The Journal of Immunology, 2005, 175: 3060–3066. http://www.jimmunol.org/ n essential feature of the cellular immune response is the expressed in fetal and adult lungs, heart, as well as several other activation of T lymphocytes. T cells are activated by organs (4, 5). It is absolutely required for normal embryogenesis A triggering the TCR/CD3 complex by a specific Ag, in and late stages of lung development (6–8). KLF2 homozygous collaboration with costimulatory and adhesion receptors. This is a null mice die in utero due to severe hemorrhage resulting from complex process that involves multiple enzymes, adapters, and defects of the mature blood vessel wall (6). KLF2 does not seem other transcriptional factors, which induces a cascade of metabolic to be a regulator of the initiation of blood vessel morphogenesis; events resulting in the transcriptional activation of a large number however, it is active in the late stages of blood vessel wall assem- of different genes (1). Of these genes, the best characterized is the bly and stabilization (7). KLF2 also appears to play an important by guest on September 25, 2021 IL-2 gene, whose induction is critical for T cell activation and role in endothelial cell activation (9, 10). differentiation. The quantity of IL-2 produced is a major determi- Additionally, KLF2 plays an important role in T cell function. nant of whether an effective response can be generated. Previous KLF2 is developmentally induced during the maturation of single- studies have indicated that several transcriptional factors, includ- positive CD4ϩ or CD8ϩ T cells and prevents mature circulating ing AP-1, NFAT, NF-␬B, and CD28RE/AP, are important positive cells from undergoing apoptosis (11, 12). Furthermore, it is re- regulators of IL-2 gene expression (2). Also, a CACCC binding quired to maintain CD4ϩ or CD8ϩ single-positive T cells in their site for specificity protein 1 and an early growth response gene-1 quiescent state (13). Also, KLF2 inhibits Jurkat T leukemia cell binding site have been recently identified immediately upstream of growth via direct up-regulation of the cyclin-dependent kinase in- the distal NFAT site (3). Because many of these transcriptional hibitor p21WAF1/CIP1 (14). Intriguingly, KLF2 is rapidly extin- factor binding sites vary from consensus sequences in other genes, guished after T cell activation and is re-expressed in CD8ϩ mem- it appears that these differences may in part account for the T ory T cells (11, 15), indicating that KLF2 might also play a crucial cell-specific expression of IL-2. role in regulating the activation of T cells and the survival of mem- Kru¨ppel-like factor 2 (KLF23; previously termed LKLF) is a ory T cells. However, the exact biological role of KLF2 in T cell member of the closely related family of the KLFs. KLF2 is highly activation is still unknown. In the studies presented in this paper, we found that KLF2 transcription and protein expression are up- Department of Molecular Genetics, Biochemistry, and Microbiology, University of regulated during the early stage of T cell activation. Moreover, the Cincinnati, College of Medicine, Cincinnati, OH 45267 expression of KLF2 significantly increases IL-2 production, up to Received for publication December 30, 2004. Accepted for publication June 22, 2005. 4-fold in activated T cells. Our studies also suggest that KLF2 The costs of publication of this article were defrayed in part by the payment of page maximally regulates IL-2 promoter activity directly via a CACCC charges. This article must therefore be hereby marked advertisement in accordance KLF2 binding site in the earlier stage of T cell activation. Our with 18 U.S.C. Section 1734 solely to indicate this fact. findings indicate that KLF2 may be required to maximally prime T 1 This work was supported by National Institutes of Health Grant RO1HL57281 (to cell activation as a novel immediate-early transcriptional factor. J.B.L.). 2 Address correspondence and reprint requests to Dr. Jerry B. Lingrel, Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati Col- Materials and Methods lege of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267. E-mail address: Plasmid constructs [email protected] 3 Abbreviations used in this paper: KLF, Kru¨ppel-like factor; ChIP, chromatin im- Full-length mouse KLF2 cDNA tagged at the C terminus with hemagglu- munoprecipitation; Dox, doxycycline; HA, hemagglutinin; mt, mutant; PPAR␥, per- tinin (HA) was generated by PCR and inserted into BamHI/HindIII restric- oxisomal proliferator-activated receptor ␥; wt, wild type. tion sites of vector pBK-CMV (Stratagene) as previously described (14). Copyright © 2005 by The American Association of Immunologists, Inc. 0022-1767/05/$02.00 The Journal of Immunology 3061 Subsequently, the insert including full-length, wild-type KLF2 (KLF2-wt) Generation of promoter constructs and site-directed mutagenesis with the HA tag was subcloned into the pTRE2hyg vector (BD Clontech) to generate Tet/KLF2 as a response plasmid for doxycycline (Dox) A 2-kb fragment of IL-2 enhancer/promoter sequence, provided by Dr. V. induction. Boussiotis (Harvard Medical School, Boston, MA) (18), was cloned into the pT81-Luc reporter vector. The Ϫ585 IL-2 promoter construct, was Cell line and stable cell transfection inserted into the SalI/BglII site of pT81-luc. The empty vector of pT81-luc, NFAT, and NF-␬B luciferase reporter constructs were gifts from Dr. D. The human Jurkat tet-on CD4ϩ T cell line (BD Clontech) was maintained McKean (Mayo Clinic, Rochester, NY) (19, 20). 4xAP-1 and CD28RE/AP in RPMI 1640 medium supplemented with 10% Tet System Approved FBS luciferase reporters were provided by Dr. X.-F. Wang (Duke University (BD Clontech), 100 ␮g/ml G418, 100 U/ml penicillin, 100 ␮g/ml strepto- Medical Center, Durham, NC) (21) and Dr. A. Weiss (University of Cal- mycin, and 100 ␮g/ml gentamicin. The transfection of 30 ␮g of Tet/ ifornia, San Francisco, CA) (22), respectively. Three additional IL-2 lu- KLF2-wt plasmid was conducted by electroporation of 2 ϫ 107 cells with ciferase deletion mutants (pIL2–310, pIL2–290, and pIL2–206) were cre- settings at 950 ␮F and 240 V, respectively. Stably transfected cells were ated to narrow down the potential KLF2-responsive sites. PCR was used to selected by growth in 200 ␮g/ml hygromycin (BD Clontech) and 200 amply these deletion mutants and to introduce a KpnI restriction site at the ␮g/ml G418 (Invitrogen Life Technologies). Clones from single cells were 5Ј end, starting from IL-2 promoter region sites Ϫ310, Ϫ290, and Ϫ206, generated by limited dilution. Protein expression was induced by resus- respectively, and the BglII restriction site at the 3Ј end, ending in the IL-2 pending cells at a density of 105/ml in complete medium with Dox transcriptional start codon (forward, 5Ј-CGAGGTACCTTTGTGTCTC (1 ␮g/ml; Sigma-Aldrich), a derivative of tetracycline.
Load more

Recommended publications
  • Determination of the Membrane Transport Properties of Jurkat Cells with a Microfluidic Device
    micromachines Article Determination of the Membrane Transport Properties of Jurkat Cells with a Microfluidic Device Tianhang Yang 1,2, Ji Peng 2, Zhiquan Shu 2,3, Praveen K. Sekar 2, Songjing Li 1,* and Dayong Gao 2,* 1 Department of Fluid Control and Automation, Harbin Institute of Technology, Harbin 150001, Heilongjiang, China; [email protected] 2 Mechanical Engineering, University of Washington, Seattle, WA 98195, USA; [email protected] (J.P.); [email protected] (Z.S.); [email protected] (P.K.S.) 3 School of Mechanical and Materials Engineering, Washington State University, Everett, WA 98201, USA * Correspondence: [email protected] (S.L.); [email protected] (D.G.); Tel.: +86-451-86418318 (S.L.); +1-206-543-1411 (D.G.) Received: 25 October 2019; Accepted: 26 November 2019; Published: 29 November 2019 Abstract: The Jurkat cell is an immortalized line of human acute lymphocyte leukemia cells that is widely used in the study of adoptive cell therapy, a novel treatment of several advanced forms of cancer. The ability to transport water and solutes across the cell membrane under different temperatures is an important factor for deciding the specific protocol for cryopreservation of the Jurkat cell. In this study we propose a comprehensive process for determination of membrane transport properties of Jurkat cell. using a novel microfluidic controlled single cell-trapping system. The osmotic behavior of an individual Jurkat cell to water and dimethyl sulfoxide (DMSO), a commonly used cryoprotective agent (CPA), under constant temperature, was recorded under a microscope utilizing the modified microfluidic system. The images of the Jurkat cell under osmotic change were processed to obtain a relationship between cell volume change and time.
    [Show full text]
  • CD28 Costimulation in Jurkat Cells Signaling Networks Triggered By
    Quantitative Analysis of Phosphotyrosine Signaling Networks Triggered by CD3 and CD28 Costimulation in Jurkat Cells This information is current as Ji-Eun Kim and Forest M. White of September 26, 2021. J Immunol 2006; 176:2833-2843; ; doi: 10.4049/jimmunol.176.5.2833 http://www.jimmunol.org/content/176/5/2833 Downloaded from References This article cites 47 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/176/5/2833.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Quantitative Analysis of Phosphotyrosine Signaling Networks Triggered by CD3 and CD28 Costimulation in Jurkat Cells1 Ji-Eun Kim and Forest M. White2 The mechanism by which stimulation of coreceptors such as CD28 contributes to full activation of TCR signaling pathways has been intensively studied, yet quantitative measurement of costimulation effects on functional TCR signaling networks has been lacking.
    [Show full text]
  • Dipropylcyclopentylxanthine Triggers Apoptosis in Jurkat T Cells by a Receptor-Independent Mechanism
    Cell Death and Differentiation (1997) 4, 639 ± 646 1997 Stockton Press All rights reserved 13509047/97 $12.00 Dipropylcyclopentylxanthine triggers apoptosis in Jurkat T cells by a receptor-independent mechanism 1 1 1 2+ Maribel Mirabet , Josefa Mallol , Carmen Lluis and Rafael apoptosis follows an increase in [Ca ]i, requires protein Franco1,2 synthesis, and is manifested by endogenous nuclease activation which results in DNA fragmentation. At the optical 1 Departament de BioquõÂmica i Biologia Molecular, Facultat de QuõÂmica, microscopy level, apoptosis can be suspected in cells Universitat de Barcelona, Catalonia, Spain presenting a nucleus with condensed chromatin (reviewed 2 correspondence author: Rafael Franco, Departament de BioquõÂmica i Biologia in McConkey et al, 1990; Cohen, 1993). Molecular, Facultat de QuõÂmica, MartõÂ FranqueÁs 1, 08028 Barcelona, Spain. Purine compounds have been widely used in the therapy tel: 343-4021208; fax: 343-4021219; email: [email protected] of proliferative diseases. 6-mercaptopurine and 6-thiogua- Received 24.3.97; accepted 12.6.97 nine were among the first to be used (Hitchings, 1991). Edited by M.L. Gougeon These compounds are metobolized in the cell and some of the resulting products interfere with DNA synthesis. Thus, replication of DNA in cancer cells does not occur and tumor Abstract cell proliferation is blocked. Recent studies have demon- strated that several purine analogs used as anticancer drugs 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX), a xanthine are cytotoxic because they induce apoptosis in proliferating analog used as selective antagonist of adenosine receptors, cells. Thus, 2-chloro-2'-deoxyadenosine and 9-b-D-arabino- caused apoptosis in a human leukemia T cell line.
    [Show full text]
  • Mining Microarray Data to Identify Transcription Factors Expressed in Naıve Resting but Not Activated T Lymphocytes
    Genes and Immunity (2004) 5, 16–25 & 2004 Nature Publishing Group All rights reserved 1466-4879/04 $25.00 www.nature.com/gene Mining microarray data to identify transcription factors expressed in naı¨ve resting but not activated T lymphocytes C Argyropoulos1,2, GC Nikiforidis2, M Theodoropoulou1, P Adamopoulos1, S Boubali3, TN Georgakopoulos4, F Paliogianni3, AG Papavassiliou4 and A Mouzaki1 1Laboratory of Hematology & Transfusion Medicine, University of Patras, Patras, Greece; 2Laboratory of Medical Physics, University of Patras, Patras, Greece; 3Laboratory of Microbiology, University of Patras, Patras, Greece; 4Laboratory of Biological Chemistry, Medical School, University of Patras, Patras, Greece Transcriptional repressors controlling the expression of cytokine genes have been implicated in a variety of physiological and pathological phenomena. An unknown repressor that binds to the distal NFAT element of the interleukin-2 (IL-2) gene promoter in naive T-helper lymphocytes has been implicated in autoimmune phenomena and has emerged as a potentially important factor controlling the latency of HIV-1. The aim of this paper was the identification of this repressor. We resorted to public microarray databases looking for DNA-binding proteins that are present in naı¨ve resting T cells but are downregulated when the cells are activated. A Bayesian data mining statistical analysis uncovered 25 candidate factors. Of the 25, NFAT4 and the oncogene ets-2 bind to the common motif AAGGAG found in the HIV-1 LTR and IL-2 probes. Ets-2 binding site contains the three G’s that have been shown to be important for binding of the unknown factor; hence, we considered it the likeliest candidate.
    [Show full text]
  • The Fate of the Nuclear Matrix-Associated-Region-Binding Protein SATB1 During Apoptosis
    Cell Death and Differentiation (2000) 7, 425 ± 438 ã 2000 Macmillan Publishers Ltd All rights reserved 1350-9047/00 $15.00 www.nature.com/cdd The fate of the nuclear matrix-associated-region-binding protein SATB1 during apoptosis J Gotzmann*,1, M Meissner1 and C Gerner1 of human diseases arise from abnormalities in apoptosis execution, resulting either in excessive removal of cells (e.g. 1 Institute of Tumor Biology ± Cancer Research, University of Vienna, A-1090 neurodegenerative diseases)5 or in inadequate accumulation Vienna, Austria of cells (e.g. cancer).6±8 Apoptosis functionally antagonizes * Corresponding author: J Gotzmann, Institute of Tumor Biology ± Cancer mitosis, as exemplified by a disturbance of a normal balance Research, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria. between proliferation and cell death during neoplastic Tel: +43-1-4277-65234; Fax: +43-1-4277-9651; 9 E-mail: [email protected] progression, a crucial step in malignant conversion. Even in most advanced malignancies the cell death machinery Received 2.9.99; revised 22.12.99; accepted 28.12.99 remains intact, but cells lack or repress regulatory mechan- Edited by SJ Martin isms to activate the death program sufficiently to balance enhanced cell production.10 Necrosis, a different form of cell death, is caused by Abstract severe damage of cellular homeostasis.5,11 Necrotic cells Special AT-rich sequence-binding protein 1 (SATB1), pre- swell and lose the protective function of the plasma dominantly expressed in thymocytes, was identified as a membrane, concomitant with anucleolytic pyknosis. Contra- rily, apoptotic cells shrink, leaving the plasma membrane component of the nuclear matrix protein fraction.
    [Show full text]
  • The Proteomic Landscape of Resting and Activated CD4+ T Cells Reveal Insights Into Cell Differentiation and Function
    International Journal of Molecular Sciences Article The Proteomic Landscape of Resting and Activated CD4+ T Cells Reveal Insights into Cell Differentiation and Function Yashwanth Subbannayya 1 , Markus Haug 1, Sneha M. Pinto 1, Varshasnata Mohanty 2, Hany Zakaria Meås 1, Trude Helen Flo 1, T.S. Keshava Prasad 2 and Richard K. Kandasamy 1,* 1 Centre of Molecular Inflammation Research (CEMIR), Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7491 Trondheim, Norway; [email protected] (Y.S.); [email protected] (M.H.); [email protected] (S.M.P.); [email protected] (H.Z.M.); trude.fl[email protected] (T.H.F.) 2 Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; [email protected] (V.M.); [email protected] (T.S.K.P.) * Correspondence: [email protected] Abstract: CD4+ T cells (T helper cells) are cytokine-producing adaptive immune cells that activate or regulate the responses of various immune cells. The activation and functional status of CD4+ T cells is important for adequate responses to pathogen infections but has also been associated with auto-immune disorders and survival in several cancers. In the current study, we carried out a label-free high-resolution FTMS-based proteomic profiling of resting and T cell receptor-activated (72 h) primary human CD4+ T cells from peripheral blood of healthy donors as well as SUP-T1 cells. We identified 5237 proteins, of which significant alterations in the levels of 1119 proteins were observed between resting and activated CD4+ T cells.
    [Show full text]
  • CD8 Co-Receptor Enhances T-Cell Activation Without Any Effect on Initial Attachment
    cells Article CD8 Co-Receptor Enhances T-Cell Activation without Any Effect on Initial Attachment Philippe Robert 1,2,*, Laurent Limozin 1,*, P. Anton van der Merwe 3,* and Pierre Bongrand 1,* 1 Laboratoire Adhesion et Inflammation, UMR INSERM 1067, UMR CNRS 7333, Aix-Marseille Université, Case 937, CEDEX 09, 13288 Marseille, France 2 Assistance Publique–Hôpitaux de Marseille, Lab. Immunologie, Hôpital de la Concception, 13005 Marseille, France 3 Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK * Correspondence: [email protected] (P.R.); [email protected] (L.L.); [email protected] (P.A.v.d.M.); [email protected] (P.B.) Abstract: The scanning of surrounding tissues by T lymphocytes to detect cognate antigens requires high speed, sensitivity and specificity. T-cell receptor (TCR) co-receptors such as CD8 increase detection performance, but the exact mechanism remains incompletely understood. Here, we used a laminar flow chamber to measure at the single molecule level the kinetics of bond formation and rupture between TCR- transfected CD8+ and CD8− Jurkat cells and surfaces coated with five peptide- exposing major histocompatibility antigens (pMHCs) of varying activating power. We also used interference reflection microscopy to image the spreading of these cells dropped on pMHC-exposing surfaces. CD8 did not influence the TCR–pMHC interaction during the first few seconds following cell surface encounter, but it promoted the subsequent spreading responses, suggesting that CD8 was involved in early activation rather than binding. Further, the rate and extent of spreading, but not the lag between contact and spreading initiation, depended on the pMHC.
    [Show full text]
  • Experimental Systems for Measuring HIV Latency and Reactivation
    viruses Review Experimental Systems for Measuring HIV Latency and Reactivation Koh Fujinaga 1,* and Daniele C. Cary 2 1 Division of Rheumatology, Department of Medicine, School of Medicine, University of California, San Francisco, CA 94143-0703, USA 2 Department of Medicine, Microbiology, and Immunology, School of Medicine, University of California, San Francisco, CA 94143-0703, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-415-502-1908 Received: 15 August 2020; Accepted: 5 November 2020; Published: 9 November 2020 Abstract: The final obstacle to achieving a cure to HIV/AIDS is the presence of latent HIV reservoirs scattered throughout the body. Although antiretroviral therapy maintains plasma viral loads below the levels of detection, upon cessation of therapy, the latent reservoir immediately produces infectious progeny viruses. This results in elevated plasma viremia, which leads to clinical progression to AIDS. Thus, if a HIV cure is ever to become a reality, it will be necessary to target and eliminate the latent reservoir. To this end, tremendous effort has been dedicated to locate the viral reservoir, understand the mechanisms contributing to latency, find optimal methods to reactivate HIV, and specifically kill latently infected cells. Although we have not yet identified a therapeutic approach to completely eliminate HIV from patients, these efforts have provided many technological breakthroughs in understanding the underlying mechanisms that regulate HIV latency and reactivation in vitro. In this review, we summarize and compare experimental systems which are frequently used to study HIV latency. While none of these models are a perfect proxy for the complex systems at work in HIV+ patients, each aim to replicate HIV latency in vitro.
    [Show full text]
  • Isolation and Characterization of NY-ESO-1–Specific T Cell Receptors Restricted on Various MHC Molecules
    Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules Michael T. Bethunea,1, Xiao-Hua Lib,1, Jiaji Yub,c,1, Jami McLaughlinb, Donghui Chengb, Colleen Mathisb, Blanca Homet Morenod, Katherine Woodse,f,g, Ashley J. Knightsg, Angel Garcia-Diazd, Stephanie Wonga, Siwen Hu-Lieskovand, Cristina Puig-Sausd, Jonathan Cebone,f,g, Antoni Ribasd,h,i,j,k, Lili Yangb,h,i,j,2, Owen N. Witteb,h,k,2, and David Baltimorea,2 aDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125; bDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095; cMolecular Biology Institute, University of California, Los Angeles, CA 90095; dDivision of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, CA 90095; eCancer Immunobiology Laboratory, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, VIC 3084, Australia; fSchool of Cancer Medicine, La Trobe University, Bundoora, VIC 3086, Australia; gCancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Heidelberg, VIC 3084, Australia; hEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095; iJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095; jDepartment of Medicine, University of California, Los Angeles, CA 90095; and kParker Institute for Cancer Immunotherapy, University of California, Los Angeles, CA 90095 Contributed by Owen N. Witte, September 26, 2018 (sent for review June 21, 2018; reviewed by Rafi Ahmed and Stephen P. Schoenberger) Tumor-specific T cell receptor (TCR) gene transfer enables specific isolate mutation-reactive, patient-specific TCRs, and to geneti- and potent immune targeting of tumor antigens.
    [Show full text]
  • Tumor-Induced Apoptosis of T Cells: Amplification by a Mitochondrial Cascade1
    [CANCER RESEARCH 60, 6811–6817, December 15, 2000] Advances in Brief Tumor-induced Apoptosis of T Cells: Amplification by a Mitochondrial Cascade1 Brian R. Gastman, Xiao-Ming Yin, Daniel E. Johnson, Eva Wieckowski, Gui-Qiang Wang, Simon C. Watkins, and Hannah Rabinowich2 Departments of Otolaryngology [B. R. G.], Pathology [X-M. Y., E. W., G-Q. W., H. R.], Pharmacology [D. E. J.], Medicine [D. E. J.], and Cell Biology and Physiology [S. C. W.], University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute [X-M. Y., D. E. J., S. C. W., H. R.], Pittsburgh, Pennsylvania 15213 Abstract cysteine proteases, play critical roles in the execution phase of apo- ptosis and are responsible for many of the biochemical and morpho- We have recently reported that apoptosis of T cells induced by squa- logical changes associated with apoptosis (5–7). Caspase-8 has been mous cell carcinoma of the head and neck (SCCHN) is partly Fas depend- identified as the most apical caspase in apoptosis induced by several ent. This tumor-induced T-cell death is mediated by the activities of 3 caspase-8 and caspase-3 and is partially inhibited by antibodies to either death receptors, including Fas and TNFR1 (8). Fas-associated death Fas or Fas ligand. We report here that in contrast to apoptosis induced by domain is recruited directly to ligated Fas or indirectly to ligated agonistic anti-Fas antibody (Ab), the tumor-induced apoptotic cascade in TNFR1, resulting in recruitment and autoactivation of caspase-8. Jurkat cells is significantly amplified by a mitochondrial loop.
    [Show full text]
  • Down-Regulation of CD4 CD4 Phosphorylation Partially Reverses
    CD4 Phosphorylation Partially Reverses Nef Down-Regulation of CD4 Yong-Jiu Jin, Xiaoping Zhang, J. Gildade Boursiquot and Steven J. Burakoff This information is current as of September 24, 2021. J Immunol 2004; 173:5495-5500; ; doi: 10.4049/jimmunol.173.9.5495 http://www.jimmunol.org/content/173/9/5495 Downloaded from References This article cites 42 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/173/9/5495.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 24, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CD4 Phosphorylation Partially Reverses Nef Down-Regulation of CD41 Yong-Jiu Jin,2* Xiaoping Zhang,‡ J. Gildade Boursiquot,* and Steven J. Burakoff*† HIV Nef down-regulates CD4 from the cell surface in the absence of CD4 phosphorylation, whereas PMA down-regulates CD4 through a phosphorylation-dependent pathway.
    [Show full text]
  • In-Vitro Anticancer Activity of Baliospermum Montanum on T Cell Leukemia - Jurkat Cell Line and Human Breast Cancer - MCF-7
    IAETSD JOURNAL FOR ADVANCED RESEARCH IN APPLIED SCIENCES ISSN NO: 2394-8442 In-vitro anticancer activity of Baliospermum montanum on T cell leukemia - Jurkat cell line and Human Breast cancer - MCF-7. Seethalaxmi Radhakrishna*1, Sarvanakumari. B.S 2 1 Research scholar, Research and Development Center Bharathiar University, Coimbatore. India 2 Professor, PG and Research Department of Microbiology, Shree Narayana Guru College, Coimbatore, India. Corresponding author - ¹[email protected] ²[email protected] Abstract:- Breast cancer and T cell leukemia are the most leading cause of death all over the world. Breast cancer is the most frequent malignancy in women and T cell leukemia is a cancer of immune system’s own T cells. Baliospermum montanum is a red listed plant with medicinal properties. In our present study we have tried to evaluate the anticancer properties of methonolic leaf extract of Baliospermum montanum against these 2 cancers using cell lines. We investigated the antiproliferative activity using MTT assay on 2 cancer cell lines MCF-7 [breast cancer] and Jurkat [T cell leukemia]. Results showed dose dependent cytotoxic effect on Jurkat and MCF-7. MCF-7 exhibited very less cytotoxicity compared to Jurkat with an IC₅₀ value of 298 µg/ml. Further analysis was carried out with Jurkat cell line. Phase contrast microscopy showed cytotoxic and apoptotic activity. DNA fragmentation analysis of Jurkat showed DNA ladder pattern commonly associated with apoptosis. Cell cycle analysis were conducted by FACS to find out the phase of growth arrest. Cell cycle arrest was 12.79% at G2/M phase whereas untreated cells 6.62%. Our study clearly demonstrates the anticancer activity of Baliospermum montanum on T cell leukemia [Jurkat cells] and can be a good source for anticancer drug.
    [Show full text]